Roche’s divarasib cuts death risk 44% versus rivals in phase III lung cancer trial

By Public Technologies
  • Roche announced phase III Krascendo 1 results showing investigational divarasib prolonged survival versus sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC.
  • Divarasib also delayed disease progression, with fewer treatment-related discontinuations and no new safety signals.
  • Results were presented at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610251130OMX_____CNEWS_EN_GNW1001279682_en) on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.